FMS European Long-Term Study

NCT00757731 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 490

Last updated 2013-07-11

No results posted yet for this study

Summary

Investigation of the long-term (12 months) efficacy and safety of milnacipran used in the treatment of fibromyalgia syndrome.

Conditions

  • Fibromyalgia Syndrome

Interventions

DRUG

milnacipran

hard capsule

DRUG

Placebo

hard capsule

Sponsors & Collaborators

  • Pierre Fabre Medicament

    lead INDUSTRY

Principal Investigators

  • Jaime C BRANCO, MD · HOSPITAL EGAS MONIZ, Lisboa, Portugal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
71 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Czechia
  • Finland
  • France
  • Germany
  • Italy
  • Norway
  • Portugal
  • Romania
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00757731 on ClinicalTrials.gov